Literature DB >> 18370506

Pharmacokinetics and tissue distribution of intravenous ofloxacin for antibiotic prophylaxis in biliary surgery.

A R Gascón1, E Campo, R M Hernández, B Calvo, J Errasti, J L Pedraz.   

Abstract

The plasma levels and tissue penetration of ofloxacin were studied after prophylactic administration in 17 patients undergoing elective biliary surgery. A single dose of ofloxacin 400mg given intravenously as an infusion was administered 1 hour before surgery. Adequate drug plasma levels [>/= minimum inhibitory concentration (MIC(90)) for Escherichia coli] were found throughout the procedure. Mean peak (1 hour) and last-determined (36 hours) ofloxacin serum levels were 7.97 +/- 3.79 mg/L and 0.19 +/- 0.13 mg/L, respectively. The elimination half-life (t((1/2)lambda)) was 8.86 +/- 3.07 hours, and the clearance and steady-state volume of distribution were 0.17 +/- 0.05 L/h.kg and 112.90 +/- 37.09L, respectively. The area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)) was 41.60 +/- 12.51 mg/L.h. In bile, ofloxacin levels were higher than in plasma and showed great variability. Adequate ofloxacin levels in subcutaneous cell tissue and gallbladder wall tissue were observed during the surgical procedure. Patients were observed daily throughout their hospital stay. This included examination of the surgical wound and recording of body temperature. No cases of anaerobic infection were noted in the study patients. Other constants such as hospitalisation stay and time of recuperation were normal for this type of surgery.

Entities:  

Year:  1998        PMID: 18370506     DOI: 10.2165/00044011-199815060-00005

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  18 in total

1.  The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection.

Authors:  D C Classen; R S Evans; S L Pestotnik; S D Horn; R L Menlove; J P Burke
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

Review 2.  Role of quinolones in surgical prophylaxis.

Authors:  L A Mandell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 3.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

4.  Postoperative wound infection: a prospective study of determinant factors and prevention.

Authors:  H C Polk; J F Lopez-Mayor
Journal:  Surgery       Date:  1969-07       Impact factor: 3.982

5.  A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls.

Authors:  M L Baum; D S Anish; T C Chalmers; H S Sacks; H Smith; R M Fagerstrom
Journal:  N Engl J Med       Date:  1981-10-01       Impact factor: 91.245

6.  Intraoperative concentrations of ofloxacin in serum, bile fluid, and gallbladder wall tissue.

Authors:  A Chin; M P Okamoto; M A Gill; D A Sclar; T V Berne; A E Yellin; P N Heseltine; M D Appleman
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

7.  Pharmacokinetics of ofloxacin and the effect on the faecal flora of healthy volunteers.

Authors:  D A Leigh; B Walsh; K Harris; P Hancock; G Travers
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

8.  Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.

Authors:  W J Wijnands; T B Vree; A M Baars; C L van Herwaarden
Journal:  Drugs       Date:  1987       Impact factor: 9.546

9.  The effects and significance of subminimal inhibitory concentrations of antibiotics.

Authors:  J A Washington
Journal:  Rev Infect Dis       Date:  1979 Sep-Oct

Review 10.  Selected overview of nongynecologic surgical intra-abdominal infections. Prophylaxis and therapy.

Authors:  S Levin; L J Goodman
Journal:  Am J Med       Date:  1985-11-29       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.